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Abstract 
 
Bone remodelling is related to coordinated phases of bone resorption and bone apposition 
allowing the maintenance of bone integrity, the phosphocalcic homeostasis all along the life 
and consequently the bone adaptation to mechanical constraints or/and to endocrine 
fluctuations. Unfortunately, bone is a frequent site of tumour development originated from 
bone cell lineages (primary bone tumours: bone sarcomas) or from non osseous origins (bone 
metastases: carcinomas). These tumour cells disrupt the balance between osteoblast and 
osteoclast activities resulting in a disturbed bone remodelling weakening the bone tissue, in a 
strongly altered bone microenvironment and consequently facilitating the tumour growth. At 
the early stage of tumour development, osteoclast differentiation and recruitment of mature 
osteoclasts are strongly activated resulting in a strong bone matrix degradation and release of 
numerous growth factors initially stored into this organic/calcified matrix. In turn these 
soluble factors stimulate the proliferation of tumour cells and exacerbate their migration and 
their ability to initiate metastases. Because Receptor Activator of NFκB Ligand (RANKL) is 
absolutely required for in vivo osteoclastogenesis, its role in the bone tumour growth has been 
immediately pointed out and has consequently allowed the development of new targeted 
therapies of these malignant diseases. The present review summarizes the role of RANKL in 
the bone tumour microenvironment, the most recent pre-clinical and clinical evidences of its 
targeting in bone bone metastases and bone sarcomas. The following paragraphs position 
RANKL targeted therapy among the other anti-resorptive therapies available and underline 
the future directions which are currently under investigations. 
 
Key words: bone cancers, bone metastases, bone sarcomas, osteoclasts, RANKL, bone 
remodeling 
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Introduction 
Bone is a very dynamic tissue resulting from coordinated phases of formation and 
resorption called bone remodelling. Additionally to its role in phosphocalcic homeostasis, 
bone remodelling process is necessary for bone growth, for renewal of cellular and 
extracellular matrix components to adapt bone organisation to the various biological and 
mechanical constraints [1-3].  Bone remodelling then leads to the renewal of around 10% of 
total bone mass each year in human. This metabolic process is based on a molecular crosstalk 
occurring between osteoblasts involved in bone apposition and osteoclasts specialized in bone 
resorption. Osteoclasts are multinucleated cells and originated from hematopoietic stem cells 
[4-6] whereas osteoblasts derived from bone marrow mesenchymal stem cells [3, 7, 8]. 
Osteoblasts control osteoclast differentiation and activation through a very complex network 
of soluble factors which act in combination with various hormones produced by endocrine 
system even if contacts between both cell types also strongly contribute to full activation of 
osteoclasts [9, 10]. Reciprocity between osteoblasts and osteoclasts can be observed as shown 
by bidirectional signalling limiting osteoclast activities and stimulating osteoblast 
differentiation [11].  
Bone remodelling can be dysregulated by oncologic events originated from bone cells 
(primary bone tumors: osteosarcoma, chondrosarcoma, Ewing’s sarcoma, etc) or from non 
osseous origins (bone metastases). Large series revealed that around 0.2% of all neoplasms 
are bone sarcomas and two new primary bone tumours arise per 100,000 persons a year [12]. 
Bone tissue is then the most frequent site of their first relapse and consequently, the incidence 
of bone metastases is relatively high and is dependent of the cancer cell types (i.e. in 70-80% 
of patients with breast or prostate cancer, in 40% of patients with lung metastases or with 
kidney cancer). Bone metastases are frequently associated with numerous clinical 
complications named skeletal-related events (SREs) and have a strong deleterious impact on 
the quality of life. SREs include pathological fractures or spinal cord compression and 
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exacerbated bone pains. All bone tumours disrupt the equilibrium between bone apposition 
and bone resorption leading on the first stop of the tumour development to an osteolytic 
process followed or not by bone forming lesions. Soluble mediators stored initially into the 
bone matrix contribute in turn to stimulate the tumor growth and to maintain the vicious cycle 
between bone and tumour cells [13].  The lost of equilibrium between bone formation and 
degradation combined with an osteomimetism behavior of cancer cells (cancer cells acquire 
bone-like properties) explains the diversity of histological features (osteolytic or bone forming 
tumours) of bone metastases [14]. Additionally, the modulation of bone micro-environment 
(“niche” concept) by cancer cells is benefit for their proliferation and also contributes to the 
drug resistance patterns [15]. 
In the late 1990’s,  two research groups in Japan and in USA have identified a 
truncated TNF receptor-like molecule (named OPG for osteoprotegerin, TNFRSF11B) 
inducing marked osteopetrosis phenotype when overexpressed in transgenic mice [16, 17]. 
One year later, RANKL (Receptor Activator of Nuclear Factor kB Ligand or TNFSF11) has 
been identified as a ligand for OPG [18, 19]. In many years, OPG/RANKL couple is became 
the principal system regulating osteoclastogenesis and bone resorption and has impressively 
stimulated the development of OPG/RANKL targeting agents for the treatment of osteolytic 
disorders in oncologic contexts or not competing with bisphosphonates, a well admitted drug 
class for the treatment of bone loss [13, 19-23].  
In all bone cancers, a strong relationship between tumour cells and bone micro-
environment has been then clearly established, facilitating the tumor development and/or the 
metastatic process. These specific communication pathways have strongly stimulated the 
research and development programs to design new drugs to treat oncologic bone diseases and 
have led specifically to the development of therapies targeting RANKL. The present review 
summarizes the most recent progresses in the treatment of bone cancers based on RANKL 
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targeting and underlines the future directions which are currently under pre-clinical 
investigations. 
 
OPG, RANK and RANKL are key protagonists controlling osteoclast biology and bone 
remodeling  
 The critical function of OPG in osteoclastogenesis has been initially revealed by the 
osteopetrotic phenotype of mice overexpressing it [18-19]. In contrast, OPG deficient mice 
exhibit osteoporotic phenotype which is totally reversed by administration of recombinant 
OPG [24]. RANKL has been identified as the main ligand of OPG known to bind RANK 
(TNFRSF11A), a transmembrane receptor of the TNFR superfamily [25]. RANKL transgenic 
mice and RANKL knockout mice are respectively osteoporotic and osteopetrotic [Figure 1]. 
In fact, membrane and soluble RANKL produced by osteoblasts interact with RANK 
expressed on monocyte lineage and osteoclast precursors, induces osteoclast differentiation 
and consequently activates bone resorption [23, Figure 1]. Discovery of the RANK/RANKL 
signalling pathway through NFkB in the osteoclast has clearly provided new insights into the 
mechanisms of osteoclastogenesis and how hormonal networks impact bone remodelling [23, 
26]. OPG is the third protagonists and acts as a decoy receptor, binds to RANKL, inhibits 
RANK-RANKL interactions and in fine is a strong anti-resorptive agent. The balance 
between bone resorption and bone apposition consequently depends on the ratio 
OPG/RANKL (Figure 1). For instance, the relative equilibrium between OPG and RANKL 
levels results to a stable bone mass, and in contrast for instance to RANKL knockout where 
bone remodeling is in favor of excessive bone formation due a marked reduction of 
osteoclastogenesis (Figure 1). Similarly, a clear relationship has been established between 
RANKL/OPG ratio and the severity of osteolysis in oncologic diseases as in benign diseases 
[27]. It is now admitted that RANKL is absolutely required for osteoclastogenesis in vivo 
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even if RANKL can be substituted in vitro by other ligands such as TNFα [28]. As the other 
TNF members, OPG, RANK and /RANKL exhibit very complex stoichiometric 
characteristics. Indeed, OPG is a dimeric molecule, even it can act as a monomer and RANL 
and RANK are homotrimeric complexes [20, 28, 29]. Additionally, OPG biology is more 
complex than those initially described and possesses numerous ligands such as other TNF 
Related Apoptosis Inducing Ligand (TRAIL) [31], proteoglycans [32] and 
glycosaminoglycans [33, 34], von Willebrand factor [35], complex VIII [36] which modulate 
its own activity.  
 
OPG, RANK and RANKL contribute to the vicious cycle established between tumour 
cells and bone microenvironment: evidences for sarcomas and carcinomas 
In bone microenvironment, OPG/RANK/RANKL molecular triad is not solely 
expressed by bone cells. Whether OPG is considered as an ubiquitary receptor [20], 
membrane RANK is expressed by various tumour cells originate from primary bone tumours 
or bone metastases, from mesenchymal and epithelial origin (Figure 2A, B). A recent study 
showed that more than 80% of bone metastases from solid tumours are RANK positive as 
revealed by immunohistochemistry [42-43]. RANK is also expressed in more than 50% of 
human osteosarcoma specimens, with preferential expression in osteosarcomas that develop in 
pathological bone and bad responders to chemotherapy [39].These observations then identify 
tumour cells as potential RANKL targets. Additionally to its expression by osteoblasts and 
bone marrow stromal cells, RANKL is produced similarly to RANK by numerous cancer cell 
types from various origins (Figure 2C). RANKL expression is modulated by a lot of 
cytokines, hormones [20] and by hypoxia dysregulating bone remodelling, a common feature 
of malignant tumors [77]. Indeed, the invasion of bone tissue by a primary or metastatic 
tumour cell precociously affects the balance between bone resorption and bone formation. 
According the tumour entities, tumour-derived factors (IGF, BMP, etc) can stimulate 
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osteoblast differentiation and activation and lead to tumour associated osteoblastic lesions 
(Figure 3) or in contrast, RANKL released by tumour cells can activate osteoclastogenesis 
and the recruitment of mature osteoclasts resulting in osteolytic lesions. The co-existence of 
both phenomenons leads to the formation of mixed osteoblastic/osteoclastic lesions. In turn, 
dysregulated bone cells-released extracellular matrix components and soluble mediators 
(TGFβ, etc) initially trapped in the bone matrix and stimulate proliferation of tumour cells and 
then the growth of tumour mass (Figure 3). This mechanism is defined as the osteoclast-
dependent role of RANK/RANKL axis in tumorigenesis. However, RANK/RANKL axis 
influences tumorigenesis through osteoclast-independent pathway (Figure 3). RANKL 
produced by bone microenvironment constitutes a fertile soil for RANK-positive tumour 
cells. Initially proposed by Paget at the end of 1900th the concept of the seed and soil for 
primary and secondary bone tumours has been strengthened by the discovery of RANKL and 
RANKL partly explains why various tumours preferentially metastasize to bone. RANKL 
released by osteoblasts and bone marrow stromal cells creates a cytokine gradient between 
bone site and extraosseous sites and triggers the migration of RANK-positive tumours cells. 
Interestingly, numerous tumour cells expressed functional RANK as shown by the signal 
transduction (P-ERK1/2, P-P38, P-IkB, etc) induced by RANKL [39, 47, 50]. The first 
evidence of this mechanism has been established by Jones et al. [45] and has been now 
described prostate carcinoma [45, 47, 48], breast carcinoma [45], oral squamous carcinoma 
[50], lung cancer cells [52] and melanoma [45]. The implication of RANK/RANKL axis in 
tumour cell migration has been confirmed by exploration in human samples. Indeed, the 
levels of RANK expressed by primary tumour cells are directly related to the occurrence of 
bone metastases in solid tumours and more specifically in breast, prostate and melanoma [42-
44]. Furthermore, RANK expression could be considered as an independent predictor of poor 
prognosis in breast cancer patients with bone metastasis in contrast with visceral metastasis 
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for which no correlation has been shown [77]. Similarly, increased RANKL expression is 
related to the migration of renal carcinoma [53]. Whether the role of functional RANK 
expression has been clarified for carcinomas, its role in the pathogenesis of sarcomas is not 
fully understood. Indeed, it has been shown that osteosarcoma cells express the RANK 
protein [39]. RANK signalling under the action of RANKL, results in the modulation of a 
panel of more than 70 specific genes demonstrating that osteosarcoma cells are therefore 
RANKL targets [40]. Wittrant et al. [38] showed that RANKL directly induces BMP-2 
expression in RANK positive osteosarcoma cells and may contribute by this way to the 
osteoblastic lesions characteristic of osteosarcomas. More recently, Lee et al. observed that 
RANKL expression is correlated to clinical behaviour of patients suffering from high-grade 
osteosarcoma [57].  
 
RANK/RANKL axis is involved in the tumorigenic process 
RANK/RANKL axis is not only associated with the bone metastastic process, and 
several arguments point out its involvement in the tumorigenicity process itself. 
RANK/RANKL may participate to the initial oncogenic program as shown by high 
expression of RANK on melanoma-initiating cells compared to the other melanoma cells [54]. 
Epithelial mesenchymal transition (EMT) is the first step allowing the extravasation and 
migration of carcinoma cells and RANKL appears clearly involved in this process. Indeed, 
Yamada et al. show that RANKL promotes EMT and induces angiogenesis independently of 
VEGF in a human head and neck squamous carinoma [78]. RANKL has also a strong impact 
on normal epithelial cells as shown by its effect on mammary gland development evidenced 
by a lactation defect in RANKL knockout mice [79, 80]. In fact, RANKL promotes the 
proliferation and survival of mammary epithelial cells [79-82] and RANK expression 
increases during the gestation more specifically at ductal branch points [82]. More 
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interestingly, whether RANKL or RANK overexpression in the mammary epithelial cells 
results in aberrant proliferation and hyperplasia of mammary glands, it directly correlates with 
preneoplasias and the development of spontaneous mammary tumours [83, 84]. Several 
authors hypothesized that RANKL may act as a paracrine factor for mammary stem cells [85, 
86]. Consequently, blockade of RANKL significantly reduces the occurrence of mammary 
tumours [84]. Overall, these data give clear evidences of the RANK/RANKL axis contributes 
to the initial steps of tumorigenesis at least for mammary glands, to the dissemination process 
of carcinoma cells and to the establishment of bone metastases. 
 
Therapies targeting RANK/RANKL axis for patients suffering from bone tumours: pre-
clinical and clinical arguments 
Given this context, targeting of RANKL signalling with its decoy receptor OPG or 
with a soluble form of its membranous receptor RANK (RANK-Fc) inhibits tumour 
associated osteolysis in several experimental bone tumour models, including rat and mouse 
primary bone tumours and bone metastases. Indeed, OPG and RANK-Fc administered by non 
viral gene transfer or as recombinant molecules are effective in preventing the formation of 
osteolytic lesions associated with osteosarcoma development and in reducing the tumour 
incidence leading to a significant increase of animal survival [87, 88]. Moreover, recent 
experiments demonstrated that RNA interference strategy targeting RANKL improved the 
tumour response to chemotherapy in a murine model of osteosarcoma [89]. Similarly, 
administration of recombinant OPG-Fc or RANK-Fc has been investigated in numerous 
murine models of bone metastases [20, 23, 79] and confirm that blockade of the 
RANK/RANKL axis is extremely efficient in preclinical assessment to prevent tumour-
induced osteolysis, to reduce tumour growth and to improve the survival rate. According these 
pre-clinical proofs of concept, recombinant OPG (OPG-Fc) has been evaluated in 
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postmenopausal [90] and in patients suffering from myeloma and osteolytic bone metastases 
(Table 1). Results demonstrated that OPG was well tolerated and demonstrated the efficacy of 
a single injection of OPG, which strongly reduced bone turnover for a sustained period and 
suppressed bone resorption as indicated by the decrease of bone resorption markers (urinary 
NTX/creatinine); these effects were comparable to those obtained with pamidronate. 
However, due to the risk of immune modulation of OPG through its binding to TRAIL [31] 
and other ligands [32-36], a fully human monoclonal antibody (IgG2) specifically targeting 
soluble and membrane RANKL has been developed [92-93]. Clinical data in osteoporotic 
patients revealed that denosumab was well tolerated with no related serious adverse events 
occurred and that a single-dose (0.01 mg/kg to 3.0 mg/kg) resulted in a dose-dependent 
sustained decrease from baseline in bone turnover [92-93]. This antibody, named denosumab 
only recognizes the human protein and its nonhuman-primate homolog and its administration 
in chimeric mice expressing murine/human leads to a strong inhibition of bone resorption 
concomitantly to an increase of the bone mineral density [94].  
Numerous clinical trials (phase II and phase III) have been then designed to evaluate 
the efficacy of denosumab in oncology mainly in breast and prostate bone metastases (Table 
1). These studies revealed that denosumab reduced significantly bone turnover markers 
similarly to osteoporotic patients. More specifically, it reduced levels of uNTX/Cr as well as 
serum TRAP5b thus showing a marked inhibition of osteoclastogenesis. According the results 
obtained, the recommendations for the use of denosumab are 120 mg s.c. every 4 months in 
oncology. Using this dose, bone resorption markers are suppressed around 90% in most 
patients independently of the tumour types [103]. Various studies have been set up to compare 
denosumab versus bisphosphonate treatment mainly zoledronic acid [95-97, 103, 109]. Single 
dose of pamidronate for instance (90 mg i.v.) reduced in a similar intensity the levels of bone 
resorption markers but the effects of denosumab were more sustained [95]. Phase III study 
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demonstrated that denosumab significantly delayed the time of first SRE (Skeletal Related 
Event) but also the risk of multiple SRE and whether zoledronic acid showed similar effects, 
statistical analyses are in favour of superiority for denosumab (Table 1). The time of disease 
progression and the overall survival rate were similar between anti-RANKL treatment and 
bisphosphonate. Zoledronic acid treatment requires a strict monitoring of kidney function due 
to its toxicity in contrast to denosumab even if a greater hypocalcemia requiring specific 
monitoring has been classically observed after denosumab treatment [111]. Additionally to 
the phase acute phase reaction observed in patients after the first administration of zoledronic 
acid, osteonecrosis of the jaw occurred infrequently after long-term treatment by nitrogen-
bisphosphonates, in around 2% of patients [97, 108, 109, 112-115]. This incidence appears 
similar in bisphosphonate- and denosumab-treated patients. Consequently, the establishment 
of meticulous oral hygiene and surgical procedures prior to the administration of 
bisphosphonates and denosumab is the best method for preventing osteonecrosis of the jaw, 
prevention being better than treatment.  In all studies, denosumab was well tolerated with the 
convenience of a subcutaneous administration and no requirement for renal monitoring. 
Overall, these clinical trials demonstrated that denosumab represents a potential treatment 
option economically viable for patients with bone metastases [116]. Very recently, a novel 
anti-RANKL antibodies derived from camelidae has been assessed in postmenopausal 
patients [117]. The results from this Phase I trial, including the one year follow-up 
information, indicate that ALX-0141 is well tolerated and can be administered safely over a 
wide range of doses. ALX-0141 exhibited a strong and sustained inhibitory effect on bone 
resorption markers. 
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The other anti-resorptive in therapies of bone cancer   
Bisphosphonates have been used successfully for many years to treat the skeletal 
complications associated with the benign and malignant bone diseases [118-121].  
Bisphosphonates became progressively a standard treatment for cancer-associated 
hypercalcemia and to control metastatic bone pain. Bisphosphonates are chemical compounds 
based on a phosphorus-carbon-phosphorus template and are characterized by their strong 
affinity for bone hydroxyapatite crystals and their anti-resorptive potency. Three families of 
bisphosphonate has been produced: the first possesses simple substituents attached to the 
central carbon and inhibits weakly the bone resorption; the second family possesses an 
aliphatic side chain containing a single nitrogen atom and exerts a more potent anti-resorptive 
activity; the third generation contain a heterocyclic substituent with one or two nitrogen atoms 
and are powerful bone resorption inhibitors and anti-tumour agents [118, 119]. The members 
of the first family which do not contain nitrogen atom are metabolised in cytotoxic analogues 
of ATP leading to cell death. Nitrogen-containing bisphosphonates inhibit the activity of two 
enzymes involved in the mevalonate pathway: farnesyl diphosphate synthase (FPP) and 
geranylgeranyl diphosphate synthase (GGPP). This inhibition results in osteoclast apoptosis 
by the strong reduction of the prenylation process, the loss of osteoclatic ruffled border and 
modifications of cell cytoplasmic actin ring [118, 119]. Additionally, nitrogen-containing 
bisphosphonates exert direct activities on tumour cells (breast, prostate, lung renal carcinoma, 
osteosarcoma, chondrosarcoma, etc) through the inhibition of prenylation mechanim which 
induces tumour-cell apoptosis, inhibits of cell proliferation, modulates tumour-cell adhesion 
and inhibits tumour-cell dissemination [118-124]. Thus, bisphosphonates inhibit the 
development of bone tumors through direct activity on tumour cells and indirect activity on 
osteoclasts. Pre-clinical revealed the therapeutic benefit of bisphosphonates for the treatments 
of primary bone tumours and bone metastases alone and combined with chemotherapy or 
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signalling pathway inhibitors [126-133]. Clinical trials have clearly confirmed their 
therapeutic interests [Table 1]. 
Since many decades, bone tumours have stimulated imagination of researchers and 
numerous therapeutic alternatives have been proposed [134, 135, Figure 4]. The better 
knowledge of OPG/RANK/RANKL system leads to the development of peptides mimicking 
OPG and blocking RANK-RANKL interactions [136-139]. Inhibitors of NF-KB signalling 
showed interesting anti-resorpive activities [140, 143]. The targeting of integrins more 
specifically αvβ3 strongly reduced the osteolytic process and the development of bone 
tumours [144-150]. Specific blockade of enzymatic activities has been envisaged with a great 
success. MMP9 involved in osteoclast migration and its targeting blocked by antisense 
oligodeoxyribonucleotide strongly affects osteoclast migration and resoption [151]. Cathepsin 
K, a key cysteine-proteinase related to osteolytic process [152, 153] stimulates a huge 
enthusiasm in the world of bone research. Several companies have then developed chemical 
inhibitors of cathepsin K to treat malignant and non-malignant bone loss with interesting 
results [154-157]. Thus, forty three women suffering from breast metastatic disease has been 
recently randomized in double-blind study to evaluate the impact of an oral cathepsin K 
inhibitors [odanacatib 5 mg daily for 4 weeks or 4 mg zoledronic acid i.v] on bone resorption 
markers [157]. Odanacatib appeared generally safe and well tolerated and has suppressed 
osteolytic markers similarly to zoledronic acid after 4 weeks of treatment. These results 
strengthen the therapeutic interest of cathepsin K for oncologic bone loss.  
 
Conclusions 
Bone tissue attracts massively tumour cells where they find a favorable environment to 
maintain the stem cell dormancy and where they find a fertile ground for their development. 
This “fatal attraction” linked to the specific bone niche, has boosted therapeutic innovations 
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targeting the tumour cells and/or their microenvironment [158]. During the last past decade, 
RANK/RANKL axis emerged in bone biology as predominant protagonists of bone 
remodeling and as therapeutic targets of bone loss diseases. Better knowledge of 
RANK/RANKL biology will better define their relevance as biomarkers in bone oncology, 
and a complete cartography of RANK expression will be very useful to predict good 
responders to anti-RANKL therapies. Although anti-RANKL therapy progressively competes 
with approaches by bisphosphonates, a lot of prospect including signal transduction inhibitors, 
peptides or enzymatic inhibitors has been already identified and pre-clinical data as well as 
clinical trials allow personalized therapies in bone oncology. 
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Figure Legends: 
Figure 1: RANKL is absolutely required for osteoclast differentiation in vivo as revealed 
by the bone phenotype exhibited by RANKL knockout mice. (A) Osteopetrotic phenotype 
exhibited by RANKL knockout (RANKL-/-) compared to wild type (WT) C57BL6 mice 
analyzed by µCT (skyscan 1076). (B) Osteoblasts produced RANKL (membrane and soluble 
forms) which binds to membrane RANK expressed by osteoclast precursors, OPG 
synthesized by osteoblasts acts as a decoy receptor, blocks the interactions RANKL/RANK 
and then inhibits bone resorption. The lack of RANKL results in a disturbed bone remodeling 
characterized by an excessive bone formation and a reduced bone resorption compared to the 
control mice. 
 
Figure 2: RANK is expressed by numerous tumour cell type. (A) Main tumour cell types 
expressing RANK; (B) RANK immunostaining on osteosarcoma [39], prostate carcinoma and 
thyroid carcinoma [51]. In all cases, RANK is expressed by cancer cells. 
 
Figure 3: Direct and indirect role of RANKL in bone tumour development. RANKL 
contributes to the development of bone tumours via the activation of osteoclastogenesis and 
bone resorption defining an osteoclast-dependent pathway. RANKL also can bind directly 
RANK-expressing tumour cells, stimulating epithelial mesenchymal transition, cell migration 
and then identifying an osteoclast-independent. Tumour cells dysregulate the balance between 
osteoblasts and osteoclasts, resulting in osteolytic, osteoblastic or osteoblastic. osteoclastic 
mixed lesions according the tumour cell type. 
 
Figure 4: Therapeutic arsenals currently used or in development targeting osteoclast 
lineage to treat bone tumours. These therapeutic approaches targets osteoclast the 
differentiation and/or their activation by blocking RANKL binding to RANK, signal 
transduction, cell adhesion and migration or enzymatic activities. 
 
Table 1: Summary of the main clinical trials in oncology assessing anti-RANKL 
therapies 
 
Clinical trials 
drug assessed 
Cancer Number of 
patients 
included 
Doses References 
Phase I OPG 
recombinant 
Bone metastases 
(Breast) 
Myeloma 
26 
 
28 
s.c. 0.1-3 mg/Kg 91 
Phase I, Denosumab Bone metastases 
(Breast) 
Myeloma 
29 
 
25 
Denosumab  
s.c. 0.1-3 mg/Kg 
Pamidronate 
90m g i.v. 
95 
Randomized, double 
blind 
Denosumab versus 
zoledronate 
Bone metastases 
(excluding breast, 
prostate and 
myeloma)  
886 
 
 
890 
Denosumab 
 s.c. 120 mg monthly 
 
Zoledronate 
 i.v. 4 mg monthly  
96 
Randomized, double 
blind 
Denosumab versus 
zoledronate 
Bone metastases 
(Breast) 
1,026 
 
 
1,020 
Denosumab 
 s.c. 120 mg monthly 
 
Zoledronate 
 i.v. 4 mg monthly 
97 
Phase II, Denosumab 
with and without 
bisphosphonate 
exposure 
Bone metastases 366 Denosumab  
s.c. 60 or 180 mg every 
12 weeks 
 
Denosumab  
s.c. 30, 120, or 180 mg 
every 4 weeks 
98-100 
Denosumab vs 
placebo and adjuvant 
aromatase inhibitors 
Non-metastatic 
breast cancer 
127 (treated) 
 
125 (placebo) 
 Denosumab  
s.c. 60 mg every 6 weeks 
101, 102 
Phase II, randomized 
trial 
Denosumab after i.v. 
bisphosphonates 
Bone metastases 
(prostate, breast 
cancers and other 
neoplasms) 
111 Denosumab s.c. 
180 mg every  
4 or 12 weeks 
103 
Phase II 
Denosumab 
 
Myeloma 96 Denosumab 
 s.c.120 mg on 
days 1, 8, and 15 
(loading doses) of cycle 
1 (28 days), and then on 
study day 29 (day 1 of 
cycle 2) and on day 1 of 
every cycle (28 days) 
thereafter 
104 
Phase II, 
Randomized 
Denosumad after 
i.v. 
bisphosphonates 
 
Bone 
metastases  
(Prostate) 
111 Denosumab  
s.c. 180 mg every 
 4 or 12 weeks 
105 
Double-blind study Prostate cancer 734 per group Denosumab 106 
Denosumad and 
androgen-
deprivation  
 s.c. 60 mg every 6 
months 
Double-blind study 
Denosumab and 
androgen-
deprivation 
Prostate cancer 734 per group Denosumab 
 s.c. 60 mg every 6 
months 
107 
Phase III 
Denosumab in 
castration-resistant 
patients 
Prostate cancer 716 per group Denosumab 
 s.c. 120 mg every 4 
weeks 
108 
Phase III, 
Denosumab versus 
zoledronate in 
castration-resistant 
patients 
Prostate cancer 950 per group Denosumab 
 s.c. 120 mg or 
zoledronate 4 mg i.v. 
every 4 weeks 
109 
Phase II 
Denosumab 
Giant cell 
tumours of bone 
37 Denosumab 
 s.c. 120 mg monthly 
110 
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